New heteroaryl HIV-protease inhibitors bearing a carbamoyl spacer were synthesized in few steps and high yield, from commercially available homochiral epoxides. Different substitution patterns were introduced onto a given isopropanoyl-sulfonamide core that can have either H or benzyl group. The in vitro inhibition activity against recombinant protease showed a general beneficial effect of both carbamoyl moiety and the benzyl group, ranging the IC50 values between 11 and 0.6 nM. In particular, benzofuryl and indolyl derivatives showed IC50 values among the best for such structurally simple inhibitors. Docking analysis allowed to identify the favorable situation of such derivatives in terms of number of interactions in the active site, supporting the experimental results. The inhibition activity was also confirmed in HEK293 mammalian cells and was maintained against protease mutants. Furthermore, the metabolic stability was comparable with that of the commercially available inhibitors.
New heteroaryl carbamates: synthesis and biological screening in vitro and in mammalian cells of wild-type and mutant HIV-protease inhibitors
Berti, Federico;
2019-01-01
Abstract
New heteroaryl HIV-protease inhibitors bearing a carbamoyl spacer were synthesized in few steps and high yield, from commercially available homochiral epoxides. Different substitution patterns were introduced onto a given isopropanoyl-sulfonamide core that can have either H or benzyl group. The in vitro inhibition activity against recombinant protease showed a general beneficial effect of both carbamoyl moiety and the benzyl group, ranging the IC50 values between 11 and 0.6 nM. In particular, benzofuryl and indolyl derivatives showed IC50 values among the best for such structurally simple inhibitors. Docking analysis allowed to identify the favorable situation of such derivatives in terms of number of interactions in the active site, supporting the experimental results. The inhibition activity was also confirmed in HEK293 mammalian cells and was maintained against protease mutants. Furthermore, the metabolic stability was comparable with that of the commercially available inhibitors.File | Dimensione | Formato | |
---|---|---|---|
BMC2019.pdf
Open Access dal 23/03/2020
Descrizione: Articolo principale
Tipologia:
Bozza finale post-referaggio (post-print)
Licenza:
Creative commons
Dimensione
977.08 kB
Formato
Adobe PDF
|
977.08 kB | Adobe PDF | Visualizza/Apri |
1-s2.0-S0968089619300926-main.pdf
Accesso chiuso
Tipologia:
Documento in Versione Editoriale
Licenza:
Copyright Editore
Dimensione
2.09 MB
Formato
Adobe PDF
|
2.09 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
1-s2.0-S0968089619300926-mmc1.docx
Accesso chiuso
Descrizione: Appendix A. Supplementary data
Tipologia:
Altro materiale allegato
Licenza:
Copyright Editore
Dimensione
7.82 MB
Formato
Microsoft Word XML
|
7.82 MB | Microsoft Word XML | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.